The COVID Advisor

Updates:  COVID-19 Vaccine Labels Updated With Expanded Warnings About Risk of Heart Inflammation (June 2025) COVID-19 Vaccine Myocarditis More Common and More Severe Than SARS-CoV-2 Infection Myocarditis: Landmark Study (2025) Damage to the heart is more common than thought after receipt of Moderna’s COVID-19 booster, a  July 2023 study  indicates. One in 35 health care workers at a Swiss hospital had signs of heart injury associated with the vaccine, mRNA-1273, researchers found. “mRNA-1273 booster vaccination-associated elevation of markers of myocardial injury occurred in about one out of 35 persons (2.8%), a greater incidence than estimated in meta-analyses of hospitalized cases with myocarditis (estimated incidence 0.0035%) after the second vaccination,” the researchers wrote in the paper, published by the European Journal of Heart Failure. In a generally healthy population, the level would be about 1 percent, the researchers said. The group experiencing the adver...

Federal  data  published by the US CDC found that 17.9% (National Estimate) of adults who previously had a COVID-19 infection are currently experiencing symptoms of long COVID. Females tend to have a relatively higher risk as compared to males. If you’re still coping with symptoms three months or more after being infected with COVID-19, you’re considered a COVID long-hauler.  As we learn more about post-COVID syndrome, however, the  definition has been refined  to be more accurate and useful: Subacute or ongoing COVID-19 (post-acute COVID-19 syndrome): symptoms continuing beyond four weeks from acute infection, up to 12 weeks. Post-acute sequelae of COVID-19 (PASC): symptoms persisting beyond the four weeks after acute infection. Post-COVID-19 syndrome (long COVID, long-hauler’s syndrome): chronic ongoing COVID-19 symptoms beyond 12 weeks from acute infection. With 200-plus symptoms linked to long COVID, treatment starts by pinpointing specific medical condition...

A newer COVID-19 variant may be causing a severe sore throat in some people who contract the infection. The variant, known as NB.1.8.1 (Nimbus), has been nicknamed by some as "razor blade throat" due to the painful symptom . Dr. McCullough appeared on Real America’s Voice Just the News with Amanda Head and said that the sore throat means the virus has been in the nasal cavity silently reproducing for at least five days before the onset of the sore throat. Because vaccines don’t work, the only way to help reduce the risk of Nimbus is twice daily nasal sprays and gargles. It must be done routinely and not just in reaction to the onset of symptoms where it is too late. COVID-19 Variant "Nimbus" NB.1.8.1 Causing 'Razor Blade Throat' by Peter A. McCullough, MD, MPH Strong Call for Twice Daily Nasal Spray and Gargle Regimen Read on Substack COVID-19 Variant "Nimbus" NB.1.8.1 Causing 'Razor Blade Throat' Strong Call for Twice Daily Nasal Spr...

Dr. Peter McCullough has impeccable academic credentials. He's an internist, cardiologist, epidemiologist, a full professor of medicine at Texas A&M College of Medicine in Dallas. He also has a master's degree in public health and is known for being one of the top five most-published medical researchers in the United States and is the editor of two medical journals. Dilute Povidone Iodine or Betadine (a 1% solution) gargling and as a nasal spray on a regular basis twice a day for prevention and then if you have been exposed or are in early stages use at least 4 or potentially 6 times a day. You can also use dilute hydrogen peroxide or dilute sodium hypo chloride or even Scope or Listerine – obviously do not swallow and spit out. Updates:  Efficacy and Advantages of Nasopharyngeal and Oropharyngeal Treatments for Early Intervention and Prophylaxis in Respiratory Viral Infections : A Systematic Review and Meta-Analysis (2025) How to Detox Sp...

Abstract: Low-cost systemic treatments, including ivermectin, hydroxychloroquine (HCQ), metformin, antiandrogens, antihistamine H1RAs, curcumin, melatonin, colchicine, probiotics, azvudine, N-acetylcysteine (NAC), fluvoxamine, nigella sativa, famotidine, and quercetin, demonstrate significant efficacy against SARS-CoV-2. This systematic review synthesizes evidence from 423 HCQ studies, 105 ivermectin studies, and numerous trials for other treatments, supported by in silico, in vitro, and animal studies. Early treatment and prophylaxis with HCQ show strong efficacy (p<0.0000000001)*, with the largest RCT reporting 57% lower symptomatic PCR+ COVID-19 (p=0.0002). Ivermectin exhibits efficacy across prophylaxis (96% lower high viral load cases), early, and late treatment (p<0.0000000001), with 36% lower long COVID risk (p<0.0001). Polytherapy enhances outcomes (68% [57-77%] risk reduction) compared to monotherapy (33% [30-36%]), driven by synergistic effects. Despite challenges li...